The US Food & Drug Administration approved BioMarin Pharmaceutical Inc.’s C-type natriuretic peptide analog Voxzogo (vosoritide) on 19 November to improve growth in children five years of age and older with achondroplasia and open epiphyses. Voxzogo is “the first therapeutic treatment option for children with achondroplasia,” BioMarin emphasized.
BioMarin’s Voxzogo Accelerated Approval Based Mostly On One-Year Data
US FDA advisory committee had encouraged a two-year endpoint for achondroplasia treatments, but BioMarin attributes success to having ‘partnered closely’ with the agency. Confirmatory trial still being discussed.
